Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Briacell Therapeutics Corp

BCTX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$3.44

▲ +0.00%

Market Cap $29.54M · Vol 9.84K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$29.54M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

46.10

Momentum

Beta

1.11

vs Market

52W High

$14.55

76.36% below

52W Low

$2.61

31.80% above

Volume

9.84K

Avg 27.79K

P/B

0.77

Price-to-book

ROE

N/A

Return on equity

Free Float

97.48%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Briacell Therapeutics Corp (BCTX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BCTX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.49%

-7.03%

-15.06%

-15.48%

YTD

-51.62%

-53.45%

-99.67%

-99.61%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-26,556,140.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-192.98% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.77
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	8.70M

Technical Indicators

50-Day SMA	$3.36
200-Day SMA	$5.32
RSI (14)	46.10
Beta	1.11
52-Week High	$14.55
52-Week Low	$2.61

Volume Today	9.84K
Avg Daily Volume (30D)	27.79K
Relative Volume	0.35x
Volatility (10D)	51.62
Volatility (30D)	62.86
Free Float	97.48%

Analyst Consensus

N/A

Current Price $3.44

Mean Target N/A

52W Low$2.61 52W High$14.55

Current

Target

$2.61 $14.55

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SMHR46

ISINCA1079303071

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.